Hua 2020.

Methods	Study design: Randomised clinical trial Study duration: December 2017 to January 2019 Setting: Hospital
Participants	Number of participants: 86 Age (mean ± SD, range ): TACE + RFA: 55.4 ± 4.57 years; TACE alone: 55.45 ± 4.25 years Male (n/total): TACE + RFA: 24/43; TACE alone: 26/43
Interventions	TACE + RFA group (n = 43): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: cisplatin 40–80 mg and epirubicin 30–50 mg RFA: The interval between TACE and RFA was 2‐4 weeks. Control group (n = 43): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: cisplatin 40–80 mg and epirubicin 30–50 mg
Outcomes	Liver function, AFP: measured by blood testing
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.